https://allsci.com/news/clinical-trials/mrna-otc-deficiency-treatment-arcturus-unveils/ AllScien 2026-09-24T16:15:42.658348Z Arcturus unveils next-generation mRNA platform with 38-fold potency boost for OTC deficiency https://allsci.com/news/clinical-trials/setidegrasib-kras-g12d-lung-cancer-astellas-opens/ AllScien 2026-09-24T16:13:06.828574Z Astellas moves KRAS G12D degrader setidegrasib into Phase III lung cancer trial https://allsci.com/news/licensing-and-partnerships/eli-lilly-innocare-partnership-expands-china/ AllScien 2026-09-24T15:25:51.135985Z Lilly expands China biotech strategy with USD 3.25b InnoCare discovery collaboration https://allsci.com/news/development/galleri-cancer-detection-test-fda-approval/ AllScien 2026-09-24T13:02:08.802096Z FDA advisory panel backs GRAIL's Galleri multi-cancer early detection test https://allsci.com/news/m-a/zymeworks-theravance-acquisition-acquires-for-usd-1/ AllScien 2026-09-24T12:53:23.615561Z Zymeworks closes out acquisition of Theravance for USD 929m https://allsci.com/news/venture-financing/ai-drug-development-funding-basecamp-research/ AllScien 2026-09-24T12:39:58.638682Z Basecamp Research scales AI-designed drug pipeline with USD 140m Series C https://allsci.com/news/clinical-trials/imvt-1402-cutaneous-lupus-immunovant-discontinues/ AllScien 2026-09-24T11:48:51.701481Z Immunovant drops IMVT-1402 in cutaneous lupus after proof-of-concept miss https://allsci.com/news/licensing-and-partnerships/variant-bio-boehringer-cardiovascular-expands-1/ AllScien 2026-09-24T11:32:17.230053Z Variant Bio expands Boehringer deal into cardiovascular disease with USD 250m at stake https://allsci.com/news/research/ai-enzyme-discovery-bacteriophages-anthropic-uses/ AllScien 2026-09-24T10:59:58.579673Z Anthropic uses autonomous AI agents to uncover novel bacteriophage enzyme system https://allsci.com/news/business/pentagon-biological-threat-contract-flagship/ AllScien 2026-09-24T10:20:59.305412Z Flagship Pioneering secures USD 47 million Pentagon contract for biological threat countermeasures https://allsci.com/news/venture-financing/ai-drug-discovery-funding-enveda-secures-usd-311/ AllScien 2026-09-24T09:55:45.644844Z Enveda secures USD 311m to advance three AI-discovered clinical-stage programs https://allsci.com/news/regulatory-designations-pathways/glm101-fda-breakthrough-designation-grants/ AllScien 2026-09-24T08:58:10.538661Z FDA grants Breakthrough status to Glycomine therapy for rare inherited metabolic disorder https://allsci.com/news/m-a/merck-kgaa-bio-techne-acquisition-clears-final/ AllScien 2026-09-23T16:45:09.675287Z Merck KGaA's USD 11.3b Bio-Techne acquisition clears final shareholder approval hurdle https://allsci.com/news/clinical-trials/cbl-514-dercums-disease-caliways-beats-placebo-in/ AllScien 2026-09-23T16:29:55.609099Z Caliway reports positive Phase IIb data for CBL-514 in Dercum’s disease https://allsci.com/news/licensing-and-partnerships/nucleic-acid-delivery-lung-mirai-bio-and-astar/ AllScien 2026-09-23T15:56:53.224702Z Mirai Bio and A*STAR team up to improve lung delivery of nucleic acid therapies https://allsci.com/news/regulatory-designations-pathways/fda-fast-track-px578-polg-disease-designation/ AllScien 2026-09-23T15:43:08.941231Z Pretzel’s POLG activator gains FDA Fast Track ahead of Phase II POLG disease trial https://allsci.com/news/grants/adaptive-red-blood-cells-darpa-scarlet/ AllScien 2026-09-23T15:29:12.634893Z Scarlet Therapeutics leads USD 14m DARPA-backed UK smart red blood cell consortium https://allsci.com/news/business/ovarian-cancer-trial-funding-oncoinvent-raises/ AllScien 2026-09-23T15:20:56.539969Z Norway’s Oncoinvent raises USD 16.2m to fund radiopharmaceutical ovarian cancer trial https://allsci.com/news/clinical-trials/sefaxersen-iga-nephropathy-roches-meets-phase-iii/ AllScien 2026-09-23T14:59:59.747652Z Roche's sefaxersen meets Phase III primary endpoint in IgA nephropathy trial https://allsci.com/news/approvals/trixeo-triple-inhaler-approval-eu-approves/ AllScien 2026-09-23T14:50:37.620598Z EU approves AstraZeneca's Trixeo as first triple-combination inhaler for inadequately controlled asthma https://allsci.com/news/business/grunenthal-stivarga-acquisition-expands-into/ AllScien 2026-09-23T14:26:58.816793Z Grünenthal expands into oncology with EUR 375 million Stivarga acquisition from Bayer https://allsci.com/news/licensing-and-partnerships/mash-liver-testing-siemens-healthineers-and-novo/ AllScien 2026-09-23T14:20:49.628261Z Siemens Healthineers, Novo partner to expand non-invasive liver fibrosis testing in MASH https://allsci.com/news/systimmune-phase-iii-lung-cancer-trial-hits-usd/ AllScien 2026-09-23T13:28:45.248756Z SystImmune hits USD 250m milestone from BMS as iza-bren Phase III lung cancer trial advances https://allsci.com/news/clinical-trials/laromestrocel-hlhs-trial-longeverons-fails-to/ AllScien 2026-09-23T10:41:41.188727Z Longeveron starts strategic review after laromestrocel failure to improve heart function in HLHS infants https://allsci.com/news/licensing-and-partnerships/t-cell-engager-license-deal-henlius-licenses-two/ AllScien 2026-09-23T10:35:09.170048Z Henlius looks to US biotech for global TCE rights in Amberstone deal https://allsci.com/news/clinical-trials/petrelintide-phase-iii-obesity-zealand-pharma/ AllScien 2026-09-23T10:05:50.690084Z Zealand launches Phase III program for amylin analog petrelintide in overweight and obesity https://allsci.com/news/clinical-trials/ulefnersen-fus-als-trial-otsukas-becomes-first-to/ AllScien 2026-09-23T09:56:01.510124Z Otsuka's ulefnersen becomes first to hit primary endpoint in placebo-controlled FUS-ALS trial https://allsci.com/news/clinical-trials/inaxaplin-amkd-phase-iib-vertex-expands/ AllScien 2026-09-23T07:05:34.751757Z Vertex posts Phase II data extending inaxaplin's reach in AMKD patient populations https://allsci.com/news/regulatory-designations-pathways/qrx003-fast-track-fda-peeling-skin-syndrome/ AllScien 2026-09-23T06:50:14.098785Z Quoin advances QRX003 in peeling skin syndrome with second FDA Fast Track https://allsci.com/news/clinical-trials/barzolvolimab-chronic-urticaria-celldexs-beats/ AllScien 2026-09-23T06:43:47.532256Z Celldex’s barzolvolimab scores pivotal CSU wins after recent setbacks https://allsci.com/news/clinical-trials/vk2735-weight-loss-maintenance-vikings-maintains/ AllScien 2026-09-22T21:42:16.276576Z Viking reports positive monthly and every-other-week VK2735 maintenance data https://allsci.com/news/development/adg138-nmpa-clearance-adagene-receives-for/ AllScien 2026-09-22T16:48:25.380312Z Adagene advancing HER2 bispecific TCE into clinic in China https://allsci.com/news/ipo-public-listing/iambic-therapeutics-ipo-files-for-backed-by-usd/ AllScien 2026-09-22T16:43:05.663547Z Iambic files for IPO after string of Big Pharma AI partnerships https://allsci.com/news/licensing-and-partnerships/friedreich-ataxia-acquisition-lexeo-expands/ AllScien 2026-09-22T16:27:28.665107Z Lexeo expands Friedreich ataxia platform with USD 21.3m Mantle acquisition and CNS collaborations